<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288053</url>
  </required_header>
  <id_info>
    <org_study_id>DIADCDAllo2005</org_study_id>
    <nct_id>NCT01288053</nct_id>
  </id_info>
  <brief_title>Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease</brief_title>
  <official_title>Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic transplantation has been a high-risk procedure, although non-myeloablative
      conditioning regimens (mini-transplantation) minimizes regimen related toxicity. The
      investigators, therefore, propose a phase I study of matched sibling allogeneic hematopoietic
      stem cell transplantation with non-myeloablative conditioning. In addition, graft versus host
      disease (GVHD) will be virtually eliminated by CAMPATH that removes donor T cells from the
      graft.

      The goal is to assess the toxicity/efficacy (phase I) of allogeneic non-myeloablative
      hematopoietic stem cell transplantation for high-risk Crohn's disease. In simplistic terms,
      this protocol is designed to ablate an aberrant immune system and then, similar to the use of
      marrow transplants for immunodeficient patients, reconstitute a new immune system with
      lymphocyte depleted marrow.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PBSC will be mobilized with G-CSF 10 mcg/kg/day (dose may be adjusted down to 5 mcg/kg/day by
      PI for toxicity, e.g. flu-like symptoms) with stem cell collection beginning on day 4 or 5.
      Leukapheresis may be repeated up to three consecutive days.

      Cyclophosphamide 60 mg/kg/day x 2 days will be given IV over 1 hour in 500 cc of normal
      saline.

      Dosage should be based on the lesser of adjusted body weight or actual weight. Mesna 50mg/day
      x 2 days will be given IV over 24 hours

      CAMPATH-1H 30mg/day x 2 days (no dose adjustment) will be given IV over 2 hours in 100 cc of
      normal saline. Premedication with Solumedrol 1g IV, Acetaminophen 650mg &amp; benadryl 50mg PO/IV
      will be given 30-60min before infusion. Also while on CAMPATH, Chlorphenamine 4 mg PO TID,
      Singular 10 mg PO daily, Pepcid 40 mg PO BID and Claritin 10 mg PO daily will be given,
      adjusted as needed. These medications can be repeated or changed as needed.

      Fludarabine 30mg/m2 daily for 3 days (no dose adjustment) will be given IV over 30 minutes in
      100 cc normal saline.

      Hydration approximately 150ml/hr should begin 2 hours before cyclophosphamide and continue
      until 24 hours after the last cyclophosphamide dose. Daily weights will be obtained. Amount
      of fluid can be modified based on patient's fluid status.

      G-CSF will be continued until absolute neutrophil count reaches at least 1,000/ul.

      Cyclosporin will be started on day -2 at 200 mg po BID and adjusted by HPLC levels to between
      150 - 250 or by toxicity (e.g., tremor, renal insufficiency, TTP, etc.). CSA will be
      continued for 30 days unless stopped for toxicity or needed to maintain donor engraftment.

      Cyclosporine and MMF guidelines dosage and duration can be modified according to
      investigators discretion based on side effects, renal function, CBC and GVHD status.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No participant enrolled more than two years. No plan to continue study.
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Up to five years</time_frame>
    <description>The number of participants who survived treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Allogeneic Stem Cell Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic Stem Cell Therapy will be performed after conditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Stem Cell Therapy</intervention_name>
    <description>Donor stem cells will be given to subject diagnosed with Crohn's disease</description>
    <arm_group_label>Allogeneic Stem Cell Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient eligibility

        Inclusion Criteria:

          1. Age &gt;18 years and less than age 45 years at time of pretransplant evaluation and,

          2. Ability to give informed consent.

        And either A or B A)An established clinical diagnosis of severe CD with disease onset
        before 16 years old (at least 71 genetic loci predispose to pediatric CD, Limbergen, JV.
        Annu. Rev. Genom. Human Genet. 2009; 10:89-116) that has failed therapy with prednisone, 5
        ASA products and has failed an anti-TNF therapy. Failure is defined as a CDAI (appendix A)
        250-400 or a Craig Severity Score that is &gt; 17 (appendix C).

        B)Relapse after an autologous HSCT with a CDAI (appendix A) 250-400 or a Craig Severity
        Score that is &gt; 17 (appendix C).

        Exclusion Criteria:

          1. HIV positive.

          2. History of coronary artery disease, or congestive heart failure.

          3. Uncontrolled diabetes mellitus or any other illness that in the opinion of the
             investigators would jeopardize the ability of the patient to tolerate aggressive
             chemotherapy.

          4. Prior history of malignancy except localized basal cell or squamous skin cancer. Other
             malignancies for which the patient is judged to be cured by local surgical therapy,
             such as head and neck cancer, or stage I breast cancer will be considered on an
             individual basis

          5. Positive pregnancy test, lactation, inability or unwillingness to pursue effective
             means of birth control, failure to accept or comprehend irreversible sterility as a
             side effect of therapy.

          6. Psychiatric illness or mental deficiency making compliance with treatment or informed
             consent impossible.

          7. FEV 1/FVC &lt; 50% of predicted, DLCO &lt; 50% of predicted.

          8. Resting LVEF &lt; 50%.

          9. Bilirubin &gt; 2.0 mg/dl, transferase (AST) &gt; 2x upper limit of normal, unless the
             abnormalities are secondary to Crohn's disease.

         10. Serum creatinine &gt; 2.0 mg/dl.

         11. Platelet count less than 100,000/ul, ANC less than 1500/ul.

         12. Patients presenting with intestinal perforation or toxic megacolon, or a suppurative
             problem that will require urgent surgery. In addition, the patient may not have any
             active infection. The presence of intestinal stomas does not exclude the patient from
             study.

         13. Pre-study peripheral blood counts must include a platelet count greater than
             100,000/ul and an absolute neutrophil count greater than 1500/ul.

         14. Creatinine clearance more than 20% below lower limit of normal for age and sex.

         15. Short gut syndrome.

        Donor eligibility

        Inclusion criteria

        1. Donor must be an HLA 6 out of 6 matched sibling

        Exclusion criteria of HLA matched sibling donor

          1. Physiologic age &gt; 50 years old or &lt;18 years old

          2. HIV positive

          3. Active ischemic heart disease or heart failure

          4. Acute or chronic active hepatitis

          5. Uncontrolled diabetes mellitus or any other illness that in the opinion of the
             investigators would jeopardize the ability of the donor to tolerate stem cell
             collection

          6. Prior history of malignancy except localized basal cell or squamous skin cancer. Other
             malignancies for which the patient is judged to be cured by local surgical therapy,
             such as (but not limited to) head and neck cancer, or stage I or II breast cancer will
             be considered on an individual basis.

          7. Positive pregnancy test

          8. Psychiatric illness or mental deficiency making compliance with treatment or informed
             consent impossible

          9. Major hematological abnormalities such as platelet count less than 100,000/ul, ANC
             less than 1000/ul

         10. Donor has history of Crohn's or ulcerative colitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Burt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>February 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <results_first_submitted>June 13, 2017</results_first_submitted>
  <results_first_submitted_qc>August 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2018</results_first_posted>
  <last_update_submitted>August 3, 2018</last_update_submitted>
  <last_update_submitted_qc>August 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Richard Burt, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allogeneic Stem Cell Therapy</title>
          <description>Allogeneic Stem Cell Therapy will be performed after conditioning
Allogeneic Stem Cell Therapy: Donor stem cells will be given to subject diagnosed with Crohn's disease</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Allogeneic Stem Cell Therapy</title>
          <description>Allogeneic Stem Cell Therapy will be performed after conditioning
Allogeneic Stem Cell Therapy: Donor stem cells will be given to subject diagnosed with Crohn's disease</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.11" spread="7.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <description>The number of participants who survived treatment</description>
        <time_frame>Up to five years</time_frame>
        <population>The number of participants who survived treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Therapy</title>
            <description>Allogeneic Stem Cell Therapy will be performed after conditioning
Allogeneic Stem Cell Therapy: Donor stem cells will be given to subject diagnosed with Crohn's disease</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>The number of participants who survived treatment</description>
          <population>The number of participants who survived treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Allogeneic Stem Cell Therapy</title>
          <description>Allogeneic Stem Cell Therapy will be performed after conditioning
Allogeneic Stem Cell Therapy: Donor stem cells will be given to subject diagnosed with Crohn's disease</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <description>One mortality due to adenovirus colitis, hepatitis, and fulminate liver failure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>While in the hospital for transplant, two patients had disease related anorexia requiring parenteral nutrition</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>perianal abscess</sub_title>
                <description>One patient had disease related perianal abscess during transplant. resolved with antibiotics and incision and drainage</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>perforated colon</sub_title>
                <description>one patient 14 months post transplant underwent surgery to remove stricture-- during surgery colon perforated-- surgery showed no evidence of crohns</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile infection (C-Diff)</sub_title>
                <description>One participant developed C-Diff infection one month after the transplant . Another participant developed C-Diff infection while inpatient for transplant. Both were treated with Flagyl and infections resolved.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>One participant was diagnosed with sinusitis four months after the transplant, treated with oral antibiotics and resolved.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Strep throat</sub_title>
                <description>One patient had strep throat resolved with oral antibiotics</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia nervosa</sub_title>
                <description>one patient had anorexia nervosa before HSCT--continued after HSCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <description>In one patient, who had prior history of Tacrolimus associated AKI (Acute Kidney Injury), post transplant was complicated by AKI. Renal biopsy showed chronic tubule-intestinal disease, started on hemodialysis.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <description>One patient two months post transplant developed cholecystitis requiring cholecystectomy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small numbers of subjects enrolled</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Richard Burt</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-4960</phone>
      <email>rburt@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

